Final answer:
Hemophiliacs lack blood clotting factors, leading to prolonged bleeding and requiring treatment such as clotting factor infusions, with genetic therapy as a potential future option.
Step-by-step explanation:
Hemophiliacs typically lack the proteins that act as blood clotting factors, crucial for the clotting process. Hemophilia is a genetic disorder characterized by the inability to produce enough functional clotting factors, such as factor VIII in Hemophilia A or factor IX in Hemophilia B. These factors are essential for stopping bleeding by forming a fibrin clot, a network of protein that traps blood cells at the site of injury.
Treatment for hemophiliacs often includes regular infusions of clotting factors, which can be derived from healthy donors. Future therapies may involve genetic therapy, offering long-term solutions to this clotting disorder.